Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity von Basler, Michael, Lindstrom, Michelle M, LaStant, Jacob J, Bradshaw, J Michael, Owens, Timothy D, Schmidt, Christian, Maurits, Elmer, Tsu, Christopher, Overkleeft, Herman S, Kirk, Christopher J, Langrish, Claire L, Groettrup, Marcus

Volltext

IL-12 and IL-23: master regulators of innate and adaptive immunity von Langrish, Claire L., McKenzie, Brent S., Wilson, Nicholas J., De Waal Malefyt, Rene, Kastelein, Robert A., Cua, Daniel J.

Volltext

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation von Murphy, Craig A, Langrish, Claire L, Chen, Yi, Blumenschein, Wendy, McClanahan, Terrill, Kastelein, Robert A, Sedgwick, Jonathon D, Cua, Daniel J

Volltext

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib) von Owens, Timothy D, Brameld, Ken A, Verner, Erik J, Ton, Tony, Li, Xiaoyan, Zhu, Jiang, Masjedizadeh, Mohammad R, Bradshaw, J. Michael, Hill, Ronald J, Tam, Danny, Bisconte, Angelina, Kim, Eun Ok, Francesco, Michelle, Xing, Yan, Shu, Jin, Karr, Dane, LaStant, Jacob, Finkle, David, Loewenstein, Natalie, Haberstock-Debic, Helena, Taylor, Michael J, Nunn, Philip, Langrish, Claire L, Goldstein, David M

Volltext

IL-25 regulates Th17 function in autoimmune inflammation von Kleinschek, Melanie A, Owyang, Alexander M, Joyce-Shaikh, Barbara, Langrish, Claire L, Chen, Yi, Gorman, Daniel M, Blumenschein, Wendy M, McClanahan, Terrill, Brombacher, Frank, Hurst, Stephen D, Kastelein, Robert A, Cua, Daniel J

Volltext

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168) von Owens, Timothy D., Smith, Patrick F., Redfern, Andrew, Xing, Yan, Shu, Jin, Karr, Dane E., Hartmann, Sonja, Francesco, Michelle R., Langrish, Claire L., Nunn, Philip A., Gourlay, Steven G.

Volltext

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design von Ucpinar, Sibel, Kwan, Joyce K., Hoffman, Joshua D., Tilley, Mera K., Douglas, Jeffrey A., Rubio, Roman G., Lu, Ruixiao, Nunn, Philip A., Langrish, Claire L.

Volltext

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease von Langrish, Claire L, Bradshaw, J Michael, Francesco, Michelle R, Owens, Timothy D, Xing, Yan, Shu, Jin, LaStant, Jacob, Bisconte, Angelina, Outerbridge, Catherine, White, Stephen D, Hill, Ronald J, Brameld, Ken A, Goldstein, David M, Nunn, Philip A

Volltext

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation von Langrish, Claire L, Chen, Yi, Blumenschein, Wendy M, Mattson, Jeanine, Basham, Beth, Sedgwick, Jonathan D, McClanahan, Terrill, Kastelein, Robert A, Cua, Daniel J

Volltext

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis von Chen, Yi, Langrish, Claire L, McKenzie, Brent, Joyce-Shaikh, Barbara, Stumhofer, Jason S, McClanahan, Terrill, Blumenschein, Wendy, Churakovsa, Tatyana, Low, Justin, Presta, Leonard, Hunter, Christopher A, Kastelein, Robert A, Cua, Daniel J

Volltext

PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen‐1 signalling von Herter, Jan M, Margraf, Andreas, Volmering, Stephanie, Correia, Benedito Eduardo, Bradshaw, J Michael, Bisconte, Angelina, Hill, Ronald J, Langrish, Claire L, Lowell, Clifford A, Zarbock, Alexander

Volltext

Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models von Xing, Yan, Chu, Katherine A, Wadhwa, Jyoti, Chen, Wei, Zhu, Jiang, Bradshaw, J Michael, Shu, Jin, Foulke, Matthew C, Loewenstein, Natalie, Nunn, Philip, By, Kolbot, Phiasivongsa, Pasit, Goldstein, David M, Langrish, Claire L

Volltext

Cutting Edge: Modulation of Intestinal Autoimmunity and IL-2 Signaling by Sphingosine Kinase 2 Independent of Sphingosine 1-Phosphate von Samy, Eileen T, Meyer, Claas A, Caplazi, Patrick, Langrish, Claire L, Lora, Jose M, Bluethmann, Horst, Peng, Stanford L

Volltext

PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura von Langrish, Claire L, Bradshaw, J Michael, Owens, Timothy D, Campbell, Robert L, Francesco, Michelle R, Karr, Dane E, Murray, Steve K, Quesenberry, Robert C, Smith, Patrick F, Taylor, Michael D., Zhu, Jiang, Nunn, Philip A, Gourlay, Steven G

Volltext

IL-12 and IL-23 von Langrish, Claire L, Mckenzie, Brent S, Wilson, Nicholas J, Malefyt, Rene De Waal, Kastelein, Robert A, Cua, Daniel J

Volltext

IL-12 and IL-23: master regulators of innate and adaptive immunity: Cytokines and Cytokine Receptors von LANGRISH, Claire L, MCKENZIE, Brent S, WILSON, Nicholas J, DE WAAL MALEFYT, Rene, KASTELEIN, Robert A, CUA, Daniel J

Volltext

IL-23 drives the expansion of pathogenic ThIL-17 cells required for autoimmune inflammation von Langrish, Claire L., Chen, Yi, Blumenschein, Wendy M., Mattson, Jeanine, Basham, Beth, Sedgwick, Jonathan D., McClanahan, Terrill, Kastelein, Robert A., Cua, Daniel J.

Volltext

Uses of Mammalian Cytokine; Related Reagents von CHEN YI, SEDGWICK JONATHON, KASTELEIN ROBERT A, RENNICK DONNA M, LANGRISH CLAIRE L, CUA DANIEL J

Volltext bestellen

Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity von CHEN YI, SEDGWICK JONATHON, KASTELEIN ROBERT A, RENNICK DONNA M, LANGRISH CLAIRE L, CUA DANIEL J

Volltext bestellen

Uses of mammalian cytokine; related reagents von CHEN YI, SEDGWICK JONATHON, KASTELEIN ROBERT A, RENNICK DONNA M, LANGRISH CLAIRE L, CUA DANIEL J

Volltext bestellen